References

  1. Conner MW, Dorian-Conner C, Vaidya VS, et al. Drug toxicity - Principles of pharmacology: The pathophysiologic basis of drug therapy, 4th edition. David E. Golan (Ed). Philadelphia, PA. Wolters Kluwer. 2017. 70-86.
  2. Williams KA, Taifour ML. Adverse Drug Reactions - Part I. dentalcare.com. Accessed July 24, 2017.
  3. Riedl MA, Casillas AM. Adverse drug reactions: types and treatment options. Am Fam Physician. 2003 Nov 1;68(9):1781-90.
  4. Belle DJ, Singh H. Genetic factors in drug metabolism. Am Fam Physician. 2008 Jun 1;77(11):1553-60.
  5. Dahlin A, Tantisira K. Pharmacogenomics - Principles of pharmacology: The pathophysiologic basis of drug therapy, 4th edition. David E. Golan (Ed). Philadelphia, PA. Wolters Kluwer. 2017. 87-95.
  6. Sevik M. Oncogenic viruses and mechanisms of oncogenesis. Turk J Vet Anim Sci 2012;36(4):323-329. Accessed July 24, 2017.
  7. Chung W. Teratogens and their effects. Accessed July 24, 2017.
  8. Council for International Organizations for Medical Sciences. Reporting adverse drug reactions. Definitions of terms and criteria for their use. Geneva. CIOMS. 2000.
  9. Roswarski M, Villa KR, Kiersma ME, et al. Prevalence of Adverse Drug Effects/Adverse Drug Reactions in 200 Most Commonly Prescribed Drugs Corrected for Prescription Volume. Pharmacy Practice Faculty Presentations. Las Vegas, NV. 2009. Accessed July 24, 2017.
  10. National Institute of Health. U.S. National Library of Medicine. DailyMed. Accessed July 24, 2017.
  11. MacNeal RJ. Approach to the dermatologic patient – The Merck manual of diagnosis and therapy, 19th edition. Robert S Porter (Ed). Whitehouse station, NJ. Merck Sharp & Dohme Corp., 2011. 632-645.
  12. Delves PJ. Allergic and other hypersensitivity reactions – The Merck manual of diagnosis and therapy, 19th edition. Robert S Porter (Ed). Whitehouse station, NJ. Merck Sharp & Dohme Corp., 2011. 1108-1125.
  13. Rehmus WE. Hypersensitivity and inflammatory disorders. – The Merck manual of diagnosis and therapy, 19th edition. Robert S Porter (Ed). Whitehouse station, NJ. Merck Sharp & Dohme Corp., 2011. 683-691.
  14. Jacobsen PL, Chávez EM. Clinical management of the dental patient taking multiple drugs. J Contemp Dent Pract. 2005 Nov 15;6(4):144-51.
  15. Torpet LA, Kragelund C, Reibel J, et al. Oral adverse drug reactions to cardiovascular drugs. Crit Rev Oral Biol Med. 2004 Jan 1;15(1):28-46.
  16. Scully C, Bagan JV. Adverse drug reactions in the orofacial region. Crit Rev Oral Biol Med. 2004 Jul 1;15(4):221-39.
  17. Berman JR, Paget SA. Approach to the patient with joint disease reactions – The Merck manual of diagnosis and therapy, 19th edition. Robert S Porter (Ed). Whitehouse station, NJ. Merck Sharp & Dohme Corp., 2011. 283-297.
  18. Alissa HM, Diamond HS. Serum sickness. Accessed July 24, 2017.
  19. Gasche Y, Daali Y, Fathi M, et al. Codeine intoxication associated with ultrarapid CYP2D6 metabolism. N Engl J Med. 2004 Dec 30;351(27):2827-31.
  20. US National Library of Medicine. DailyMed. Minocin - minocycline hydrochloride capsule, coated pellets. Triax Pharmaceuticals, LLC. Updated 12/13. Accessed July 24, 2017.
  21. US National Library of Medicine. DailyMed. Doxycycline hyclate capsules - doxycycline hyclate capsule. Hikma Pharmaceutical. Updated 9/09. Accessed July 24, 2017.
  22. Czeizel AE, Rockenbauer M. A population-based case-control teratologic study of oral oxytetracycline treatment during pregnancy. Eur J Obstet Gynecol Reprod Biol. 2000 Jan;88(1):27-33.
  23. Liew Z, Ritz B, Rebordosa C, et al. Acetaminophen use during pregnancy, behavioral problems, and hyperkinetic disorders. JAMA Pediatr. 2014 Apr;168(4):313-20. doi: 10.1001/jamapediatrics.2013.4914.
  24. U.S. Department of Health and Human Services. U.S. Food and Drug Administration. Safety. MedWatch. The FDA Safety Information and Adverse Event Reporting Program. Reporting Serious Problems to FDA. Instructions for Completing Form FDA 3500. Accessed July 24, 2017.

Additional Resources

  • No Additional Resources Available